Evidence map›Paper›PMID 24530497›Full record

ArticleMolecular and cellular endocrinology2014

D-chiro-inositol glycan stimulates insulin secretion in pancreatic β cells.

Roman Lazarenko, Jessica Geisler, Douglas Bayliss, Joseph Larner, Chien Li

Abstract read
In one paragraph

Article in Molecular and cellular endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Roman LazarenkoDepartment of Pharmacology, University of Virginia Health System, Charlottesville, VA, United States.
Jessica GeislerDepartment of Pharmacology, University of Virginia Health System, Charlottesville, VA, United States.
Douglas BaylissDepartment of Pharmacology, University of Virginia Health System, Charlottesville, VA, United States.
Joseph LarnerDepartment of Pharmacology, University of Virginia Health System, Charlottesville, VA, United States.
Chien LiDepartment of Pharmacology, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: cl4xd@virginia.edu.
University of Virginia Health System · US

Funding

Molecular Bases for Motoneuronal NeuromodulationR01NS033583 · NINDS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI BAYLISS, DOUGLAS A. · 2001 to 2011
$3.2M
Central Neural Function of Urocortin 3 in Regulating Energy BalanceR01DK078049 · NIDDK · UNIVERSITY OF VIRGINIA · PI LI, CHIEN · 2009 to 2013
$1.6M
NIDDK NIH HHS R01 DK-078049NIDDK NIH HHS R01 DK078049NINDS NIH HHS R01 NS033583NINDS NIH HHS R01 NS33583
6 · The paper itself

Abstract

Insulin has been shown to act on pancreatic β cells to regulate its own secretion. Currently the mechanism underlying this effect is unclear. INS-2, a novel inositol glycan pseudo-disaccharide containing D-chiro-inositol and galactosamine, has been shown to function as an insulin mimetic and a putative insulin mediator. In the present study we found that INS-2 stimulates insulin secretion in MIN6 β cells and potentiates glucose stimulated insulin secretion in isolated mouse islets. Importantly, INS-2 failed to potentiate insulin secretion induced by tolbutamide, which stimulates insulin release by closing ATP sensitive potassium channels (KATP). Electrophysiological studies showed that INS-2 inhibited sulfonylurea-sensitive KATP conductance. The effect of INS-2 on inhibiting KATP channel is mediated by protein phosphatase 2C (PP2C), as knocking down PP2C expression in MIN6 cells by PP2C small hairpin RNA completely abolished the effect of INS-2 on KATP and consequently attenuated INS-2 induced insulin secretion. In conclusion, the present study identifies a novel mechanism involving PP2C in regulating KATP channel activity and consequently insulin secretion.

Indexed as

AnimalsCell LineDisaccharidesHypoglycemic AgentsInositol PhosphatesInsulinInsulin-Secreting CellsInsulin SecretionKATP ChannelsMaleMiceMice, Inbred C57BLPatch-Clamp TechniquesPhosphoprotein PhosphatasesPolysaccharidesProtein Phosphatase 2C4-(2-amino-2-deoxygalactopyranosyl)-3-O-methylinositolDisaccharidesHypoglycemic Agentsinositol phosphate glycanInositol PhosphatesInsulinKATP ChannelsPhosphoprotein PhosphatasesPolysaccharidesProtein Phosphatase 2CRNA, Small InterferingSulfonylurea ReceptorsTolbutamideINS-2Insulin secretionIsletK(ATP)MIN6PP2C

Identifiers

PMID24530497
PMCPMC4366192
OpenAlexW2011507941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.